How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
19
SOLTF Quote, Financials, Valuation and Earnings
Last price:
$6.16
Seasonality move
:
12.54%
Day range:
$6.16 - $6.16
52-week range:
$6.16 - $13.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.79x
P/B ratio:
1.17x
Volume:
--
Avg. volume:
137
1-year change:
-37.04%
Market cap:
$553.6M
Revenue:
$91M
EPS (TTM):
-$0.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SNBIF
SanBio
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical
|
$7.2B | -- | 0.1% | -- | $16.03 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
$6.16 | -- | $553.6M | -- | $0.00 | 0% | 2.79x |
|
AMGXF
AnGes
|
$0.36 | -- | $86.6M | -- | $0.00 | 0% | 22.98x |
|
HLOSF
Healios KK
|
$1.35 | -- | $121.7M | -- | $0.00 | 0% | 32.00x |
|
PPTDF
PeptiDream
|
$17.15 | -- | $2.2B | 20.38x | $0.00 | 0% | 7.14x |
|
SNBIF
SanBio
|
$4.65 | -- | $329.8M | -- | $0.00 | 0% | 78.05x |
|
TAK
Takeda Pharmaceutical
|
$13.17 | $16.03 | $41.8B | 21.79x | $0.33 | 4.7% | 1.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
48.92% | 1.984 | 55.24% | 3.73x |
|
AMGXF
AnGes
|
-- | 2.635 | -- | 1.10x |
|
HLOSF
Healios KK
|
65.07% | -0.707 | 34.39% | 1.33x |
|
PPTDF
PeptiDream
|
25.75% | -2.667 | 6.45% | 3.28x |
|
SNBIF
SanBio
|
-- | -0.161 | -- | -- |
|
TAK
Takeda Pharmaceutical
|
42.19% | 0.312 | 78.44% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
$48.9M | $5.4M | -2.75% | -5.58% | 11.44% | $10.3M |
|
AMGXF
AnGes
|
$259.5K | -$13M | -37.32% | -22.74% | -1559.14% | -- |
|
HLOSF
Healios KK
|
$2.8M | -$1.8M | -55.94% | -137.21% | -24.5% | -$4.8M |
|
PPTDF
PeptiDream
|
$17.4M | -$854.5K | 24.02% | 34.66% | -1.5% | $173.8M |
|
SNBIF
SanBio
|
-- | -$6.2M | -- | -- | -- | -$10.9M |
|
TAK
Takeda Pharmaceutical
|
$5.3B | $1.8B | 2.37% | 4.01% | 15.97% | $1.3B |
Nxera Pharma vs. Competitors
-
Which has Higher Returns SOLTF or AMGXF?
AnGes has a net margin of 12.96% compared to Nxera Pharma's net margin of -2947.39%. Nxera Pharma's return on equity of -5.58% beat AnGes's return on equity of -22.74%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M AMGXFAnGes31.07% -$0.11 $158.3M -
What do Analysts Say About SOLTF or AMGXF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than AnGes, analysts believe Nxera Pharma is more attractive than AnGes.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 AMGXFAnGes0 0 0 -
Is SOLTF or AMGXF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or AMGXF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or AMGXF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than AnGes quarterly revenues of $835.2K. Nxera Pharma's net income of $8.1M is higher than AnGes's net income of -$24.6M. Notably, Nxera Pharma's price-to-earnings ratio is -- while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 22.98x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M AMGXFAnGes22.98x -- $835.2K -$24.6M
-
Which has Higher Returns SOLTF or HLOSF?
Healios KK has a net margin of 12.96% compared to Nxera Pharma's net margin of -107.23%. Nxera Pharma's return on equity of -5.58% beat Healios KK's return on equity of -137.21%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M HLOSFHealios KK86.35% -$0.04 $57.8M -
What do Analysts Say About SOLTF or HLOSF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than Healios KK, analysts believe Nxera Pharma is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 HLOSFHealios KK0 0 0 -
Is SOLTF or HLOSF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or HLOSF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or HLOSF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than Healios KK quarterly revenues of $3.2M. Nxera Pharma's net income of $8.1M is higher than Healios KK's net income of -$3.4M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M HLOSFHealios KK32.00x -- $3.2M -$3.4M
-
Which has Higher Returns SOLTF or PPTDF?
PeptiDream has a net margin of 12.96% compared to Nxera Pharma's net margin of -5.57%. Nxera Pharma's return on equity of -5.58% beat PeptiDream's return on equity of 34.66%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M PPTDFPeptiDream47.13% -$0.02 $551.4M -
What do Analysts Say About SOLTF or PPTDF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than PeptiDream, analysts believe Nxera Pharma is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 PPTDFPeptiDream0 0 0 -
Is SOLTF or PPTDF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.
-
Which is a Better Dividend Stock SOLTF or PPTDF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or PPTDF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than PeptiDream quarterly revenues of $36.8M. Nxera Pharma's net income of $8.1M is higher than PeptiDream's net income of -$2.1M. Notably, Nxera Pharma's price-to-earnings ratio is -- while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M PPTDFPeptiDream7.14x 20.38x $36.8M -$2.1M
-
Which has Higher Returns SOLTF or SNBIF?
SanBio has a net margin of 12.96% compared to Nxera Pharma's net margin of --. Nxera Pharma's return on equity of -5.58% beat SanBio's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M SNBIFSanBio-- -$0.08 -- -
What do Analysts Say About SOLTF or SNBIF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than SanBio, analysts believe Nxera Pharma is more attractive than SanBio.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 SNBIFSanBio0 0 0 -
Is SOLTF or SNBIF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison SanBio has a beta of -0.336, suggesting its less volatile than the S&P 500 by 133.637%.
-
Which is a Better Dividend Stock SOLTF or SNBIF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or SNBIF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than SanBio quarterly revenues of --. Nxera Pharma's net income of $8.1M is higher than SanBio's net income of -$5.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 78.05x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M SNBIFSanBio78.05x -- -- -$5.8M
-
Which has Higher Returns SOLTF or TAK?
Takeda Pharmaceutical has a net margin of 12.96% compared to Nxera Pharma's net margin of 7.83%. Nxera Pharma's return on equity of -5.58% beat Takeda Pharmaceutical's return on equity of 4.01%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M TAKTakeda Pharmaceutical66.47% $0.19 $83.8B -
What do Analysts Say About SOLTF or TAK?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 20.8%. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 TAKTakeda Pharmaceutical3 1 0 -
Is SOLTF or TAK More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.
-
Which is a Better Dividend Stock SOLTF or TAK?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.7% to investors and pays a quarterly dividend of $0.33 per share. Nxera Pharma pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or TAK?
Nxera Pharma quarterly revenues are $62.4M, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Nxera Pharma's net income of $8.1M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 21.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 1.39x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
